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Abstract
Studies of multiple measures of a quantitative trait can have greater precision and thus statistical 
power compared to single measure studies, but this has rarely been studied in the relation to 
quantitative trait measurement error models in genetic association studies. Using estimated 
glomerular filtration rate (eGFR), a quantitative measure of kidney function, as an example we 
constructed measurement error models of a quantitative trait with systematic and random error 
components. We then examined the effects on precision of the parameter estimate between genetic 
loci and eGFR resulting from varying the correlation and contribution of the error components. 
We also compared the empirical results from 3 genome-wide association studies (GWAS) of 
kidney function in 9049 European Americans: a single measure, a 3-measure model of the same 
biomarker of kidney function, and a 6-measure model of different biomarkers of kidney function. 
Simulations showed that given the same amount of overall errors, inclusion of measures with less 
correlated systematic errors led to greater gain in precision. The empirical GWAS results 
confirmed that both the 3- and 6-measure models detected more eGFR-associated genomic loci 
with stronger statistical association than the single-measure model despite some heterogeneity 
among the measures. Multiple measures of a quantitative trait can increase the statistical power of 
a study without additional participant recruitment. However, careful attention must be paid to the 
correlation of systematic errors and inconsistent associations when different biomarkers or 
methods are used to measure the quantitative trait.
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Introduction
Genome-wide association studies (GWAS) have discovered many robust, albeit modest, 
genetic associations for quantitative traits.(1) This is facilitated through large consortia that 
are comprised of many individual studies to attain appropriate statistical power. While 
increasing sample size can enhance statistical power by increasing the precision of the 
genetic parameter estimate, another way to increase the precision is to increase the number 
of phenotype measures per individual. In epidemiological studies, multiple measures of a 
phenotype within an individual can represent either: 1) repeated measures from a single 
assessment method, (e.g. weight over multiple years) or 2) multiple measures assessed using 
different methods (e.g. weight, percent body fat, waist-to-hip circumference to represent 
obesity). The impact of multiple measures on the precision of the genetic parameter, and 
hence the required sample size, will depend on the systematic and random errors of the 
phenotypic measurement and the correlations between the measures within each individual. 
Formulas and procedures exist for calculating sample size for detecting associations with 
correlated data.(2, 3) However, the impact of different types of measurement errors and the 
application of multiple measure models in GWAS remains to be evaluated.
We therefore performed a simulation study, along with examination of an empirical dataset, 
to assess how different types of measurement errors affect the precision of the genetic 
parameter estimate in genetic association analyses of multiple measures. Both the simulation 
and the empirical studies were based on estimated glomerular filtration rate (eGFR), a 
quantitative marker of kidney function. GFR is often estimated using serum creatinine 
(eGFRscr) because the direct measure of GFR is often impractical in both clinical and 
research settings.(4) Other biomarkers, such as serum cystatin C (CysC), beta trace protein 
(BTP), and beta-2 microgobulin (B2M), have also been used as kidney function biomarkers.
(5–8) In the estimation of GFR, there will be systematic errors that are the properties of each 
biomarker, and there will also be random errors due to day-to-day physiological change and 
laboratory measurement errors.
In the simulation study, we examined the impact of systematic and random errors, along 
with increasing the number of phenotypic measures, on the precision of the genetic 
parameter estimate. In the empirical data analysis, we aimed to answer the following 
questions: (1) to what extent do the longitudinal measures of eGFR based on serum 
creatinine increase the precision of the genetic parameter estimate; and (2) does the addition 
of measures based on non-creatinine biomarkers provide further gain in the precision and 
reduce bias in detecting genetic associations?
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GFR Measurement Error Model—In our GFR measurement error models, the observed 
outcome, Yij (representing eGFR or any other biomarker-based kidney function index), was 
determined by three latent components: 1) an individual’s average stable true GFR (tGFR); 
2) systematic errors (εS), including biomarker specific inter-individual variability, unrelated 
to the true GFR and not accounted for in the GFR estimating equation; and 3) random errors 
(εR), such as laboratory measurement errors and within-individual day-to-day physiological 
variations in GFR or biomarker levels. For the jth and kth observations of individual i, the 
correlation between the outcomes, (Yij,Yik), was determined by tGFR and systematic errors, 
which may or may not be correlated within an individual depending on the method of 
measurement. In our specification of the measurement error model, the three latent 
components of the outcome (tGFR, systematic errors and random errors) were assumed to 
be independent with standard normal distribution, Normal (0, 1). Figure 1 presents a GFR 
measurement error model of two measures. Details of the specification of the measurement 
error model are described in the Supplementary Methods section.
Evaluation of Datasets with Complete Data—Using four models (summarized in 
Table 1), we investigated the impact of varying 1) the overall measurement errors, and 2) the 
correlation between the systematic errors, (εSij, εSij), on the gain in precision of the genetic 
parameter estimate in multiple measure models. We assumed the causal SNP explained 
0.5% of tGFR variance without measurement errors. The contribution of tGFR to the 
variance of the outcome, Yij, was set to 0.7 in models 1 and 2, and reduced to 0.5 in models 
3 and 4. Therefore, the percentage of the variance of Yij explained by the SNP was 0.35% 
for models 1 and 2 and 0.25% for models 3 and 4, similar to the modest effect size of the 
index SNPs in eGFR GWAS results (9). The setting of 0.7 for the contribution of tGFR in 
models 1 and 2 was based on unpublished data from the Modification of Diet in Renal 
Disease (MDRD) Study and the African American Study of Kidney Disease (AASK). In 
these two studies, the correlation between eGFR and tGFR, estimated from urinary 
clearance of 125I-iothalamate (gold standard), was approximately 0.9 in patients with 
chronic kidney disease. This implies the contribution of tGFR to the variance of eGFR was 
approximately 0.81 (=0.92). In the general population the contribution of tGFR to eGFR 
variance would be lower (10).
In models 1 and 2, the contribution of random errors to the variance of the outcome was set 
at 0.1 based on the estimates of within-individual variation in serum creatinine (11) and 
measured GFR (11, 12). Therefore, the contribution of systematic errors to the variance of 
the outcome was set to 0.2 (=1 − 0.7 − 0.1). The contributions of systematic errors in models 
3 and 4 were kept at the same level. The systematic errors, (εSij, εSij), where j ≠ k, were 
assumed to be uncorrelated in models 1 and 3, and have a covariance of 0.5 in models 2 and 
4.
From the GFR measurement error model parameters described above, we estimated the 
observed covariance of the outcomes and the residual variance of a generalized least square 
(GLS) regression model (Table 1). GLS is a common method for modeling multiple 
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correlated continuous outcomes and can estimate the association between a predictor and the 
outcomes taking into account correlated residuals. In this paper, we reserve the term “errors” 
to refer to the latent error components in the measurement error model and use “residuals” to 
refer to the portion of the outcome unexplained by predictor(s) in a GLS regression model.
We expressed the gain in precision of the genetic parameter estimate in a multiple measure 
model over a single measure model in term of the estimated “change in equivalent sample 
size”. The formula for the estimate of the gain in precision is provided in Supplementary 
Methods section. This measure is relevant in situations where an investigator might be 
deciding between increasing power through additional recruitment of study participants 
(thus increasing Yi) or adding another outcome measure in the existing population (adding 
Yik). Equivalent sample size was defined as the sample size in a single measure ordinary 
least square (OLS) regression that would provide the same power as a multiple measure 
model using GLS given the same effect size and alpha level.
Evaluation of Datasets with Data Missing Completely at Random—Based on the 
above measurement error models, we simulated datasets with sample sizes of either 3,000 or 
6,000 to assess the impact of randomly missing data on the gain of precision in the genetic 
parameter estimate in multiple-measure models. The mechanism of missing completely at 
random (MCAR) (15) was deemed to be appropriate for this study because our focus was 
the gain in precision of the parameter estimate instead of evaluating biases in parameter 
estimate. Each dataset had three repeated outcome measures, Yi1, Yi2, and Yi3, with a 
variance of 1 and a constant modest SNP effect size (β=0.075*SD of Yij). If the SNP has an 
allele frequency of 35%, it would explain about 0.25% of the variance of Yij, similar to the 
SNP effects in models 3 and 4 in Table 1. Missing data rates in scenario 1 were 10% for the 
second measure and 25% for the third measure. The rates increased to 20% and 40% in 
scenario 2. With each missing data scenario, we simulated datasets with correlations 
between Yij and Yik ranging from 0.5 to 0.8. Since the SNP effect was assumed to be 
constant across the outcome measures, the change in the correlations between Yij and Yik 
was assumed to be solely due to the change in the correlation of systematic errors (εS). 
Residuals were generated with a distribution of Normal(0, 1) and then transformed to have 
the desired correlation by multiplying the Cholesky decomposition of a variance-covariance 
matrix. Supplementary Table 1 presents the simulation parameters. Ten thousand iterations 
were performed for datasets with a sample size of 3,000, and 6,000 iterations were 
performed for datasets with a sample size of 6,000.
With each dataset, we performed three analyses: 1) an OLS regression using the first 
measure (Yi1) as outcome, 2) a GLS regression using Yi1 and Yi2 as outcomes, and 3) a 
GLS regression using Yi1, Yi2, and Yi3 as outcomes. Changes in equivalent sample size 
were calculated using equation 3 based on the variance of the SNP parameter estimates 
generated in the simulations. To obtain the 95% interval of the variance of the SNP 
parameter estimate, we sampled the standard errors (SE) of the SNP parameter estimates in 
the single and multiple measure models separately, then calculated the square of the ratio of 
the SEs. After repeating this procedure 1000 times, we obtained the 0.025 and 0.975 
percentile for the 95% interval. SAS 9.2 PROC GLM was used for OLS regression, and 
PROC MIXED with the repeated statement was used for GLS regression. A template of the 
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SAS macro for running the association analysis was included in the Supplementary 
Materials.
Empirical Data
Study Population—The ARIC Study is a prospective observational cohort study of 
15,792 middle age adults (baseline age between 45 and 64) in four US communities. Details 
of the study design were reported previously (16). Since the known genomic risk loci for 
reduced eGFR were detected in populations of European ancestry, only the ARIC European 
American cohort (n=9,049) was included in this analysis.
Phenotype and Genotype in Empirical Dataset—In the ARIC study, the following 
measures of kidney function were available: three repeated measures of serum creatinine 
(SCr) at visits 1, 2, and 4 and measures of serum cystatin C (CysC), beta trace protein 
(BTP), and beta-2 microglobulin (B2M) at visit 4 (Supplementary Figure 1). The 
Supplementary Methods section reports the measurement methods of these biomarkers and 
the calculation of the outcome measures: eGFR based on serum creatinine (eGFRscr) and 
cystatin C (eGFRcys) and scaled BTP and B2M. Over two million imputed single nucleotide 
polymorphisms (SNPs) were evaluated in the analysis. Details on genotyping and quality 
control are reported in the Supplementary Methods section.
GWAS Statistical Analysis—Three genome-wide scans were performed: 1) a single-
measure model using eGFRscr at visit 1 as outcome, 2) a 3-measure model using eGFRscr at 
visits 1, 2, and 4 as outcomes, and 3) a 6-measure model using the three repeated measures 
of eGFRscr and the measures of eGFRcys, scaled BTP and scaled B2M as outcomes. 
Covariates included age, gender, study center, and the first 10 principal components with 
significant association with the outcome (p<0.05). The 3- and 6-measure models 
additionally included visit as a categorical covariate. The single-measure model was 
analyzed using ProbABEL (17). The multiple-measures models were analyzed using SAS 
9.2 PROC MIXED with the repeated statement and a pre-specified variance-covariance 
matrix to optimize performance. The Supplementary Methods section reports the generation 
of this variance-covariance matrix.
We calculated the genomic control factor (λGC) for the results of each genome-wide scan to 
assess possible test statistic inflation and corrected the p-values when λGC > 1.(18) The 
model comparisons were based on the genomic control corrected p-value (PValGC).
In addition, for the index SNPs of 16 known eGFR loci (9), we performed separate 
regression analyses using standardized outcome measures to obtain standardized SNP 
parameter estimates and standard errors of the single measure model and the 3- and 6-
measure models.
Comparisons of the Single- and Multiple-Measure Models in the Empirical 
Dataset—The assumption of constant effect size across measures did not hold in the 
empirical data because the association between a SNP and a biomarker could change over 
time, and the association between a SNP and different biomarkers could vary. Therefore, we 
did not use the change in equivalent sample size as a metric for comparison in the empirical 
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study. Instead we compared the effect estimates of the index SNPs of the 16 known eGFR 
loci from the single-, 3-, and 6-measure models and the change in standard error due to 
multiple measures. Next, we compared the GWAS results of the three models with respect 
to the number of loci with PValGC < 5×10−8. Only SNPs with minor allele frequency 
(MAF) > 5% were included.
Results
Effect of Multiple Measures on Change in Equivalent Sample Size Assuming Complete 
Data
Figure 2A shows the relationship between the change in equivalent sample size and the 
number of outcome measures in the four models described in Table 1. Figure 2B shows the 
reciprocal of equivalent sample size as required sample size. Equivalent sample size may be 
more intuitive when an investigator only has the option of obtaining new measures given a 
fixed sample size; whereas the change in required sample size may be useful when an 
investigator have the option of varying both the numbers of measures or participants. For 
these results, we varied the following parameters: 1) the number of outcome measures, 2) 
the total measurement errors, and 3) the correlation between systematic errors.
Under the assumptions of no missing data and constant effect size across measures, adding 
additional outcome measures always led to a gain in estimated equivalent sample size. 
Assuming an uncorrelated residual variance, σ2, of 0.3 as in model 1, an increase of up to 10 
measures led to 37% gain in equivalent sample size; however, this gain leveled off around 
five or six measures.
The relative gain in equivalent sample size with each additional measure was determined by 
the uncorrelated residual variance, σ2, as shown in equation 2. For a fixed total measurement 
error, as in models 1 and 2, the model with less correlated systematic errors, εS, had 
relatively higher uncorrelated residual variance, σ2, and resulted in more gain in equivalent 
sample size. For example, in model 1, the addition of a second measure led to an 18% gain 
in equivalent sample size but only 11% in model 2. Model 3 outperformed model 4 for the 
same reason.
Next, we also compared the impact of varying both the total measurement error and the 
correlation between systematic errors. Comparing models 2 and 3, model 2 had lower 
overall measurement errors but higher correlated residuals due to correlated systematic 
errors. The higher correlated residuals in model 2 led to a smaller gain in precision than 
model 3 with each additional measure. After the fifth measure, model 3 exceeded model 2 in 
estimated equivalent sample size.. Supplementary Table 2 presents the changes in equivalent 
sample size with 95% confidence interval for sample sizes of 3000 and 10,000. Even though 
the estimate of the expected gain in equivalent sample size with additional measures is 
independent of the sample size when assuming complete data, the 95% confidence intervals 
of the estimate are narrower with larger sample size.
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Effect of Multiple Measures on Change in Equivalent Sample Size Assuming Data Missing 
Completely At Random
Supplementary Table 3 shows the change in expected equivalent sample size when the data 
were missing completely at random. Similar to the results based on complete data, the gain 
in equivalent sample size was higher when the residuals were less correlated. As expected, 
higher missing data rate resulted in less gain in equivalent sample size with each additional 
outcome measure. When the outcome measures had a correlation of 0.5, the gains in 
equivalent sample size for adding a second measures with 0%, 10% and 20% missing data 
were 33%, 30% and 27% respectively. Even with a missing data rate as high as 40%, there 
was still gain in equivalent sample size.
Application to Kidney Function Measures in ARIC
Supplementary Table 4 reports the sample sizes, means, standard deviations, and 
correlations of the outcome measures of kidney function in the empirical study. The 
correlations between eGFRscr across the three visits ranged from 0.63 to 0.69. The 
correlations between eGFRscr and measures of kidney function based on other biomarkers 
were lower. The lowest correlation was 0.34 between eGFRscr at visit 1 and scaled BTP at 
visit 4, and the highest correlation was 0.72 between eGFRcys and scaled B2M both at visit 
4.
Comparison of the results for 16 known eGFR-associated SNPs
We tested for the associations between kidney function and the index SNPs (with the SNP 
with the lowest p-value) at 16 known eGFR-associated loci using 1) a single-measure model 
with eGFRscr at visit 1 as the outcome, 2) a 3-measure model including eGFRscr from visits 
1, 2, and 4; 3) a 6-measure model including both the repeated and the multiple measures of 
kidney function derived from different biomarkers; 4) a single-measure model with eGFRscr 
at visit 4 as the outcome and the comparison of this results with a 4-measure model 
including all four measures of kidney function at visit 4.
Overall, for most of the 16 index SNPs, the multiple measure models resulted in lower 
association p-values due to the gain in precision of the beta estimates of the SNP effect 
(Supplementary Figure 3, Supplementary Table 5). The standard error reduction of the 
multiple-measures models over the single-measure model was 12% for the 3-measure model 
and 21% for the 6-measure model. Compared with the single-measure model, the 3-measure 
model had 15 index SNPs with lower p-values; five of them were at least one order of 
magnitude lower. Again, compared with the single-measure model, the 6-measure model has 
12 index SNPs with lower p-value; seven of them were at least one order of magnitude 
lower. The 6-measure model resulted in larger pvalue than the single measure model at four 
loci due to weaker associations of the index SNPs with the non-creatinine biomarkers at 
TFDP2 and ANXA9 and opposite effect directions of the index SNPs with scaled BTP at 
PIP5K1B and DAB2. Supplementary Figure 4 shows the standardized beta estimates of the 
16 index SNPs when regressed separately against the outcomes calculated from the four 
biomarkers at visit 4 of the ARIC study. For 8 of the 16 index SNPs, the beta estimates 
against eGFRscr were larger than those against the non-creatinine-based outcomes. For the 
index SNPs of three loci (ATXN2, PIP5K1B, and DAB2), the beta estimates against scaled 
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BTP were in opposite directions from the estimates against the other three outcomes. 
Supplementary Table 6 presents the 95% confidence intervals of the estimates and p-values. 
Compared with the single measure model of eGFRscr at visit 4 versus the 4-measure model 
at visit 4, all the beta estimates were in the same direction. The standard error reduction 
from the four model was approximately 18%. However, only nine of the 16 SNPs had lower 
p-values in the 4-measure model (Supplementary Table 7).
GWAS Results
To determine whether the additional outcome measures would result in the identification of 
additional kidney loci in genome-wide scans, we performed three GWAS analyses. With 
respect to loci that reached genome-wide significance (PValGC <5×10−8), the single-
measure model identified one locus (NAT8), the 3-measure model identified three loci 
(NAT8, SHROOM3, and SPATA5L1), and the 6-measure model identified two loci (NAT8, 
SHROOM3, Supplementary Table 8). All loci had previously been discovered and replicated 
in a much larger sample.(9) One of the significant loci from the 3-measure model of 
eGFRscr, SPATA5L1, was not significant in the 6-measure model. This locus has been 
suspected to be a genetic locus related to creatinine production rather than kidney function, 
as evidenced by the lack of association with non-creatinine kidney function biomarkers.(9) 
One of the genes in this locus, GATM, encodes the rate-limiting enzyme in creatinine 
biosynthesis (19). This 6-measure model result suggests that the non-creatinine-based 
biomarkers reduced biases due the correlated systematic errors of the creatinine-based 
outcomes.
Discussion
Using both simulated and empirical datasets, we showed that increasing the number of 
outcome measures per individual led to gains in equivalent sample size, thus a gain in 
power, in genetic association analyses when the genetic effects were similar across 
measures. In addition, less correlated systematic errors led to greater gains in equivalent 
sample size. The marginal gain decreased with each additional measure and leveled off 
around the addition of the fifth or sixth measure. Lui and Cumberland made similar 
observations in the situation of 2-group complete balanced data.(20) The gain in equivalent 
sample size was relatively robust to data missing completely at random as the gain persisted 
even when the missing data rate was as high as 40%.
The results from our simulation study were corroborated by the results from the empirical 
study of multiple measures of kidney function in the ARIC study. We showed that inclusion 
of eGFRscr from 3 separate study visits (the 3-measure model) was more powerful than the 
single-measure model using eGFRscr at visit 1. However, the addition of other biomarkers 
of kidney function, including eGFRcys, scaled BTP and scaled B2M, did not make the 6-
measures model more powerful than the 3-measures model despite additional gain in the 
precision of the SNP parameter estimates due to the heterogeneity of SNP associations with 
the different biomarkers. While longitudinal repeated measures of a trait can be used to 
estimate change over time, our study focused on the use of repeated measures to detect 
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associations that are similar across multiple measures. We estimated the mean effect over 
time and not change over time.
When studying multiple measures of an outcome, one can consider either repeated measures 
using the same method or multiple measures of an underlying trait using different methods, 
such as the use of different biomarkers for kidney function in this work. The contrast 
between these two scenarios was represented by the results of the 3-measure model and the 
6-measure model from our empirical study. For repeated measures of the same outcome, 
correlated systematic errors between the multiple measures of the outcome may limit the 
gain in precision of the SNP parameter estimate. When using multiple measures based on 
different methods to represent one underlying trait, some measures may contain additional 
measurement errors, which reduce the statistical power of the study. In the kidney function 
empirical study, the inclusion of additional non-creatinine-based outcomes did not identify 
more loci with lower p-values. The non-creatinine-based outcomes may have more 
measurement errors due to the lack of population-based equations for calculating eGFR 
based on these biomarkers. Therefore, regardless of the number of measures, well-measured 
phenotypes that minimize measurement errors are important for detecting associations, a 
topic that has been studied extensively.(21)
A few studies have used repeated measures in the setting of genome-wide association 
studies and have found mixed results with respect to the gain in efficiency. Rasmussen-
Torvik et al.(22) compared the results from using the average of 4 repeated measures of 
fasting glucose over 12 years (N=5,782) to the results from 4 separate GWASs of fasting 
glucose from each study visit (N ranged from 8,372 at visit 1 to 6,421 at visit 4) and found 
that, despite a smaller sample size, the results from the analysis of the average fasting 
glucose values were stronger. the p-values of the index SNP at five candidate regions were 
lower by three to eight orders of magnitude, mostly due to reduction in standard errors. This 
suggests the average of a trait can reduce intra-individual variations and lead to stronger 
statistical associations. On the other hand, Malhotra et al. conducted genome-wide 
association studies of body mass index (BMI) that used up to 17 repeated measures and the 
maximum BMI (from 1965 to 2004) in 1,120 Pima Indians.(23) No genome-wide significant 
loci were identified. Of the 20 top SNPs reported from the repeated measure analysis, nine 
had p-values that were lower than their corresponding p-values from the analysis using the 
maximum BMI, and the differences in p-values were less than two orders of magnitude. The 
gain in efficiency from the repeated measures was not apparent, which is possible if 
maximum BMI captures an individual’s overall disposition toward obesity better than 
repeated measures of BMI over a very long period of time where BMI might fluctuate 
greatly.
One limitation of our work is that we only used GLS for analyses of multiple outcome 
measures and did not evaluate other methods. Ferreira and Purcell proposed the use of 
canonical correlation analysis for analyzing correlated outcomes in GWA studies.(24) Coin 
et al proposed using multiple phenotypes as predictors and a genetic variant as outcome in a 
regression model.(25) Both of these methods require the use of complete data. In addition, 
as it was shown in the GFR measurement error model, the correlation between measures can 
come from two sources: the true measure of the trait of interest and correlated systematic 
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errors, which does not help the detection of genetic associations of the trait. Therefore, the 
application of methods for combining multiple measures requires some assumptions and 
understanding of the measurement error model of the trait of interest.
Other limitations of this work include the assumption of one tGFR and constant covariance 
of outcomes in the measurement error models. The underlying latent trait may change over 
time, and the covariance structure among outcome measures may be complex. However, the 
basic conclusion of this work holds for multiple latent traits and complex covariance 
structures. Regardless of the specific covariance structure, correlated systematic errors 
reduce the gain in precision when using multiple measures.
GWAS provide a systematic, unbiased way to identify genes and pathways underlying a 
biological process.(26, 27) Very large sample sizes have been used to increase the precision 
of the genetic parameter estimates, thus increasing the power to identify loci of modest 
effect sizes.(28) Increasing sample size through additional participant recruitment can be 
expensive and sometimes not feasible. Therefore, using multiple measures of an outcome is 
another way to increase the statistical power of a study, especially for population-based 
cohort studies that have often collected multiple measures for prospective analyses of an 
outcome. Our findings can inform the choice of measures in the design of a multiple 
measure study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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GFR Measurement Error Model. The SNP effect is assumed to act solely through tGFR. Yij 
is a function of tGFR, systematic errors (εs) and random errors (εr). The elements with 
dotted lines shows the process of estimating GFR based on biomarker levels and are not part 
of the measurement error model.
Notations and assumptions:
• tGFR: true GFR, average stable GFR, standardized to N(0, 1)
• i: individual
• j or k: observation within an individual
• rGFR: tGFR level not explained by the SNP
• Yij: outcome in regression model, calculated from biomarker level using an 
equation, f(), representing estimated GFR
• εS : systematic errors in Yij
• εR : random errors in Yij
• εS, εR ~ N(0, 1)
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(A) Change in equivalent sample size % in the four measurement error models. The 
equivalent sample sizes of models 3 and 4 were indexed to the sample size of model 1 
accounting for the smaller beta of the genetic parameter estimate due to the smaller 
contribution of tGFR. (B) Change in required sample size (=1/equivalent sample size)% 
from the four measurement error models.
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